Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the Dow ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere ...

Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

Learn more about whether Organon & Co. or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting Roche's (RHHBY) Actemra. Read more here.

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...